GSK: Jemperli Accepted for Priority Review by the US FDA for DMMR/MSI-H Locally Advanced Rectal Cancer
August 25, 2026
August 25, 2026
LONDON, England, Aug. 25 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Aug. 24, 2026:
* * *
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
* Submission supported by AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment
* If approved, Jemperli could elimin . . .
* * *
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
* Submission supported by AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment
* If approved, Jemperli could elimin . . .